GLP-1 Agonists Market Size, Share & Trends Analysis Report By Product (Branded GLP-1 Agonists, Dual / Triple, Biosimilars & Generic GLP-1 Agonists Agonists), By Indication (Type 2 Diabetes Mellitus, Obesity / Overweight Management, Cardiovascular & Metabolic Related Indications, Other Emerging Indications (e.g., NASH, Alzheimers-related)), By Route of Administration, By Distribution Channel, By Region and By Segments Forecasts, 2025-2034 GLP-1 Agonists Market Size is valued at USD 43.1 Bn in 2024 and is predicted to reach USD 260.1 Bn by the year 2034 at an 19.9% CAGR during the forecast period for 2025-2034
"A young man escalated his dose of retatrutide, he experienced secretory diarrhoea, which was very severe, and he was admitted to hospital requiring a lot of intravenous fluid rehydration," Dr Holt said
Our dedicated team of clinicians provides round-the-clock guidance and support to answer your questions and address your concerns, ensuring you feel confident in your treatment plan
Astrocytic insulin signaling couples brain glucose uptake with nutrient availability
Once past the adjustment phase, the majority of people report feeling significantly better both physically and in daily energy levels
Leah Joseph explains the differences in dosing schedules, effectiveness, side effect profiles, and administration methods to help patients choose the option that fits their needs best
